Navigation Links
Prefilled Syringes Market (2nd Edition), 2014-2024
Date:8/4/2014

NEW YORK, Aug. 4, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prefilled Syringes Market (2nd Edition), 2014-2024

http://www.reportlinker.com/p02243611/Prefilled-Syringes-Market-2nd-Edition-2014-2024.html

INTRODUCTION

Prefilled syringes are gaining strong acceptance in the market as drug delivery systems for injectable drugs. They have become a preferred device for parenteral administration of drugs, mainly used for treatment of chronic conditions requiring patients to self-administer medication several times a week.

The origins of these syringes can be traced back to early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced syringes as drug delivery devices for heparins in Europe. Prefilled syringes were introduced initially as just a niche market product and their applications were limited to a few vaccines and anticoagulant products. Now they have been around for more than two decades and are used in all major therapeutic classes for injectable drug formulations. Owing to their numerous benefits over conventional delivery systems, prefilled syringes have become indispensable in the medical field. This is evident from our research during which we identified a large number of instances where prefilled syringes are being used to administer vaccines, anticoagulants, multiple sclerosis drugs, anti-arthritic drugs, anti-anaemic drugs and drugs from other classes. In addition, prefilled diluent syringes and flush syringes are also increasingly finding wider adoption. With pharma companies viewing prefilled syringes as a potent life cycle management tool, the pipeline is rich and growing rapidly.

The rising demand has also driven the manufacturers to introduce improvements in technology related to the material of prefilled syringes and lubrication (to reduce leachables and extractables). These developments will aid an increasing number of biologic drugs to reach the market. Additionally, the companies have developed multi-chamber prefilled syringes for use with lyophilised drugs. In our research, we have looked at how these developments and other factors are shaping the market and discussed the factors creating opportunities for various stakeholders in the market.

SCOPE OF THE REPORT

The 'Prefilled Syringes Market' report provides a comprehensive analysis of the state of prefilled syringes market. Starting with the basic introduction to prefilled syringes, their origin, components, and manufacturing material, this report talks about needlestick injuries and looks at the safety laws and legislations across major regional markets for injectable delivery. A key objective of the report is to enumerate various prefilled syringe systems available in the market, drugs available in these syringes and the corresponding market potential across different geographical regions. We have discussed various historical / likely future trends which have shaped / will shape the US, European, Japanese, Chinese and Rest of the World markets (such as India and Indonesia). We have also included a brief overview of biologics and biosimilars, one of the primary growth drivers of this market.

The study focuses on analysing the existing market size and potential future growth of these drug delivery devices across different drug therapeutic classes and regions. The forecast, over the next ten years, has been presented both in terms of volume (number of units) and value (USD billion). It takes into account the likely price variation which will occur as a result of mass adoption and increased competition. Owing to uncertainty surrounding the adoption of prefilled syringes in newer drug classes (which are currently in pipeline), we have done a multi-variate sensitivity analysis to understand the range of market growth scenarios.

In an effort to identify existing gaps and future opportunities, we have discussed the leading global prefilled syringe manufacturers in the industry, analysed their product portfolio and the likely future developments driven by these companies. We have also put emphasis and provided details on local manufacturers which are very well positioned to take advantage of the emerging home consumer markets.

The market forecasts across different segments and regions have been presented till 2024. 2013 is the base year; actual figures have been sourced and analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.

EXAMPLE HIGHLIGHTS

1. The global prefilled syringes market is likely to grow at a compounded annual growth rate (CAGR) of 11.3% between 2013 to 2024. By 2024, we expect the market to achieve sales of around 12.4 billion prefilled syringes.
2. Vaccines, diluent and flush syringes are likely to be some of the key growth areas. The emergence of biologics will be a major growth driver; growth in the long-term will be fuelled by pipeline drugs and the rising adoption in developing markets.
3. Increasing number of suppliers now provide ready to fill/ sterile prefilled syringes, which make up more than 80% of the prefilled syringes market. The integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
4. Developed markets of the US and EU together accounted for 80% of the prefilled syringes market in 2013. With the increasing adoption in China and rest of the world markets, this domination is likely to decline; by 2024, we expect the share of US and EU markets to slip to ~60%.

5. The market is highly consolidated and is currently dominated by key global players such as Becton Dickinson, Gerresheimer, MGlas AG, SCHOTT and Nuova Ompi. Other companies, which are relatively new entrants (e.g. West Pharmaceutical Services, Unilife and Vetter Pharma) are likely to foster more innovation.
6. Many regional players, especially in China, Japan and other Asian economies, have also recently surfaced to exploit the opportunity offered by large home consumer markets.

RESEARCH METHODOLOGY

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of prefilled syringes market.

Chapter 3 provides a general overview of prefilled syringes including their origin, components, types, and manufacturing material. We have also listed the major prefilled syringes available and presented a high level market landscape.

Chapter 4 highlights the key growth drivers of prefilled syringes market. These include the growing trend of self-injection, rise in chronic diseases, changing patient demographics and growth of biologics. The chapter also talks about needlestick injuries and various preventive laws worldwide which have put the focus on safety features in prefilled syringes.

Chapter 5 highlights the leading therapeutic drug classes available in prefilled syringes. Also provided is a list of top ten drugs in prefilled syringes with three case studies. For each therapeutic class, we have identified the drugs available in prefilled syringes and estimated patent expiry; we have also looked at the biosimilars currently in development.

Chapter 6 details the technological developments in prefilled syringes market focusing on syringes being manufactured for lyophilised drugs.

Chapter 7 provides profiles of the key manufacturers of prefilled syringes. Each company profile includes information on financial performance, geographical presence, marketed devices, role and strategy for manufactured devices and recent developments.

Chapter 8 highlights the regional prefilled syringe manufacturers; we have briefly profiled the key players in Chinese, Japanese and Indian markets.

Chapter 9 provides the SWOT analysis of prefilled syringes market giving strategic insights in to the major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that can negatively impact the growth.

Chapter 10 analyses the regional markets (the US, Europe, Japan, China and RoW) for prefilled syringes. Within each region, the chapter focuses on the market size and various technological, commercial and regulatory details

Chapter 11 provides a detailed description of the likely evolution of prefilled syringes market. We have adopted a 'bottom-up' approach to identify the likely size of the market, both in terms of volume (number of units, in billions) and value (in USD billion).

Chapter 12 is a collection of interview transcripts. For the purposes of our study, we contacted a number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry.

Chapter 13 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides a list of companies and organisations mentioned in this report.

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO PREFILLED SYRINGES
3.1. What are Prefilled Syringes?
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits for Manufacturers
3.3.3. Shift of Existing Formulations to PFS
3.4. Prefilled Syringe Components
3.5. Classification of Prefilled Syringes
3.5.1. Manufacturing Material of Barrel
3.5.1.1. Glass: Historical Material of Choice
3.5.1.2. Limitations of Glass Prefilled Syringes
3.5.1.3. Addressing the Limitations of Glass Prefilled Syringes
3.5.1.4. Advantages of Plastic Prefilled Syringes
3.5.1.5. Slow Adoption of Plastic Prefilled Syringes
3.5.1.6. Factors Likely to Drive the Use of Plastic Prefilled Syringes
3.5.2. Single-Chamber and Dual-Chamber
3.5.3. Type of Needle
3.5.4. Type of Processing
3.6. Prefilled Syringe Systems Available in the Market
3.7. Glass Prefilled Syringes
3.8. Plastic Prefilled Syringes

4. GROWTH DRIVERS
4.1. Increase in Number of Self-injecting Patients
4.2. Increase in Incidence of Chronic Diseases
4.3. Changing Patient Demographics
4.4. Growth of Biologics and Biosimilars
4.5. Changing Pharmaceutical Strategies Driving Demand for Prefilled Syringes
4.6. Auto-Injectors / Pen-Injectors
4.6.1. Convergence of Prefilled Syringes with Autoinjectors
4.6.2. Pen Injectors vs. Autoinjectors
4.7. Needlestick Injuries and Safety Systems
4.7.1. Incidence and Cost Burden
4.7.2. Government Legislation for Needlestick Injury Prevention
4.7.3. Safety Mechanism Used by Prefilled Syringe Manufacturers
4.7.3.1. Unifill Safety Syringes
4.7.3.2. MedPro Prefilled Safety Syringes
4.7.3.3. Fulject Safety Syringes
4.7.3.4. LyoTwist Dual-Chambered Pen-Injector

5. PRODUCTS AVAILABLE IN PREFILLED SYRINGES
5.1. Drugs Approved in Prefilled Format in 2013-2014
5.2. Leading Drugs (By Sales) in Prefilled Format, 2013
5.2.1. Case Study: Humira (Adalimumab), AbbVie /Eisai
5.2.1.1. Indications and Dosage Forms
5.2.1.2. Humira: Launched in Prefilled Syringe
5.2.2. Case Study: Enbrel (Etanercept), Amgen/Pfizer/Takeda
5.2.2.1. Indications and Dosage Forms
5.2.2.2. Enbrel: Move from Vial to Syringes
5.2.3. Copaxone (Glatiramer acetate), Teva Pharmaceuticals
5.2.3.1. Indications and Dosage Forms
5.2.3.2. Copaxone: Move from Vial to Syringes
5.3. Other Drugs Available in Prefilled Format, 2014

5.4. Pipeline Products, 2014
5.5. Drugs Available by Therapeutic Classes, 2014
5.5.1. Anti-rheumatics
5.5.1.1. Approved Injectables
5.5.1.2. Biosimilars Anti-rheumatics
5.5.2. Multiple Sclerosis (MS)
5.5.2.1. Approved Injectables
5.5.2.2. Biosimilars Multiple Sclerosis
5.5.3. Anticoagulants
5.5.3.1. Approved Injectables
5.5.3.2. Biosimilars/Generics Anticoagulants
5.5.4. Anti-virals
5.5.4.1. Approved Injectables
5.5.4.2. Biosimilars Anti-virals
5.5.5. Anti-Diabetes Market
5.5.5.1. Anti-diabetic Drugs Available in Prefilled Syringes
5.5.6. Vaccines Market
5.6. Contrast Agents Available in Prefilled Syringes

6. TECHNOLOGICAL DEVELOPMENT IN PREFILLED SYRINGES
6.1. Chapter Overview
6.2. Prefilled Syringes for Lyophilised Drugs
6.2.1. Prefilled Diluent Syringes
6.2.2. Lyophilised Drugs Available in Prefilled Diluent Syringe Systems
6.2.3. Dual/Multi-Chamber Syringes
6.2.4. Lyophilised Drugs Available in Dual/Multi-Chamber Prefilled Syringe
6.2.5. Prefilled Dual-Chambered Pen Injectors for Lyophilised Drugs
6.2.6. Prefilled Reconstitution Systems for Lyophilised Drugs

7. LEADING GLOBAL PREFILLED SYRINGE MANUFACTURERS
7.1. Chapter Overview
7.2. Becton Dickinson (BD)
7.2.1. Company Overview
7.2.2. Financial Performance, 2013
7.2.3. Glass Prefilled Systems
7.2.3.1. BD Hypak Syringe System
7.2.3.2. BD Neopak Syringe System
7.2.4. Plastic Prefilled Systems
7.2.4.1. BD Sterifill Syringe Systems

7.2.5. Auto-injectors / Pen-injectors
7.2.5.1. BD Uniject
7.2.5.2. BD Physioject
7.2.6. Other Devices
7.2.7. Other Prefilled Delivery Systems
7.2.8. Safety Systems: Add-On Devices
7.2.9. BD Prefilled Technology Solutions
7.2.10. Recent Developments
7.2.10.1. Deals and Agreements
7.2.10.2. Expanding Prefilled Syringe Portfolio
7.2.10.3. Entering the Generic Business
7.2.10.4. Expanding the Safety Device Portfolio
7.2.11. Development Pipeline

7.3. Gerresheimer
7.3.1. Company Overview
7.3.2. Financial Performance, 2013
7.3.3. Glass Prefilled Systems
7.3.3.1. Gx Glass Syringes
7.3.4. Plastic Prefilled Systems
7.3.4.1. ClearJect Plastic Syringes

7.3.5. Safety Systems: Add-On Devices
7.3.6. Insulin Pens
7.3.7. Finishing Processes
7.3.8. Recent Developments
7.3.8.1. Expansion of Product Portfolio
7.3.8.2. Expansion of Manufacturing Capacity for RTF Syringes
7.3.8.3. Medical Plastic Systems Capacity Expansion
7.3.8.4. Growing Interest in Emerging Economies

7.4. Nipro Corporation (acquired MGlas AG)
7.4.1. Company Overview
7.4.2. Financial Performance, 2013
7.4.3. Glass Prefilled Systems
7.4.4. Recent Developments
7.4.4.1. Acquisition of MGlas AG

7.5. SCHOTT
7.5.1. Company Overview
7.5.2. Financial Performance, 2013

7.5.3. Glass Prefilled Systems
7.5.3.1. syriQ (previously Forma 3s) Glass Syringes
7.5.3.2. syriQ InJentle Syringes
7.5.4. Plastic Prefilled Systems
7.5.4.1. TopPac Polymer Syringes
7.5.5. Recent Developments
7.5.5.1. TopPac Syringe System for Highly Viscous Drugs
7.5.5.2. TopPac 20 ml Syringe System for Infusion Therapy
7.5.5.3. Rebranding of the Glass PFS
7.5.5.4. Looking To Grow in the Pharmerging Markets (Brazil, China, India, Indonesia, and Russia)
7.5.5.5. Production Facility in the US and EU Likely to Provide Advantage

7.6. Nuova Ompi
7.6.1. Company Overview
7.6.2. Glass Prefilled Systems
7.6.2.1. EZ-fill Syringes
7.6.3. Recent Developments
7.6.3.1. New Corporate Branding
7.6.3.2. Capacity Expansion Across the Glass Division

7.7. Other Prefilled Syringe Manufacturers
7.7.1. West Pharmaceutical Services
7.7.1.1. Company Overview
7.7.1.2. Financial Performance, 2013
7.7.1.3. Plastic Prefilled Systems
7.7.1.4. Autoinjectors and Other Systems
7.7.1.5. Safety Systems: Add-On Devices
7.7.1.6. Prefilled Technology Solutions
7.7.1.7. Syringe Components
7.7.1.8. Recent Developments
7.7.1.9. Development Pipeline
7.7.2. Unilife Corporation
7.7.2.1. Company Overview
7.7.2.2. Financial Performance, 2013
7.7.2.3. Glass Prefilled Systems
7.7.2.4. Autoinjectors
7.7.2.5. Wearable Injector Platform
7.7.2.6. Ocular Delivery Systems
7.7.2.7. Novel Delivery Systems
7.7.2.8. Recent Developments

7.7.3. Vetter Pharma
7.7.3.1. Company Overview
7.7.3.2. Lyo-Ject Glass Prefilled Systems
7.7.3.3. Safety Systems: Add on Devices
7.7.3.4. Recent Developments

8. REGIONAL PREFILLED SYRINGE MANUFACTURERS
8.1. Chinese Prefilled Syringe Manufacturers
8.1.1. Shandong Weigao Group Pharmaceutical Packaging Company Ltd.
8.1.2. Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
8.1.3. Shandong Pharmaceutical Glass Co., Ltd.
8.1.4. YangZhong Wealth Metal Co., Ltd.
8.1.5. Youlyy Industrial Co., Ltd.

8.2. Japanese Prefilled Syringe Manufacturers
8.2.1. Terumo Corporation
8.2.1.1. Company Overview
8.2.1.2. Financial Performance, 2013
8.2.1.3. Plajex: Plastic Prefilled Systems
8.2.1.4. Safety Devices: Add-On Devices
8.2.2. Taisei Kako Co., Ltd.
8.2.2.1. Company Overview
8.2.2.2. VF-Syringe Glass Prefilled Syringes
8.2.2.3. ClearJect Plastic Prefilled Syringes
8.2.2.4. Fulject Plastic Prefilled Syringes
8.2.3. ARTE CORPORATION
8.2.3.1. Company Overview
8.2.3.2. Arte Prefillable Syringes
8.2.4. J.O. Pharma Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd)

8.3. Indian Prefilled Syringe Manufacturers
8.3.1. Roselabs Group
8.3.1.1. Company Overview
8.3.1.2. Glass Prefilled Systems
8.3.1.3. Plastic Prefilled Systems

8.3.1.4. Recent Developments

9. SWOT ANALYSIS
9.1. Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats

10. LEADING REGIONAL MARKETS FOR PREFILLED SYRINGE SYSTEMS, 2014 - 2024
10.1. The US Market for Prefilled Syringes, 2014
10.1.1. Prefilled Syringes are Combination Products
10.1.1.1. Regulation of Combination Products in the US
10.1.1.2. Regulatory Approval of Prefilled Syringes in the US
10.1.2. Trends in the US Prefilled Syringes Market

10.2. European Market for Prefilled Syringes, 2014
10.2.1. Combination Products in Europe
10.2.2. Regulatory Approval of Prefilled Syringes in Europe
10.2.3. Trends in the European Prefilled Syringe Market
10.2.3.1. Europe is the Preferred Destination for Manufacturing Prefilled Syringes

10.3. The Chinese Market for Prefilled Syringes, 2014
10.4. Rest of the World Markets for Prefilled Syringes, 2014
10.4.1. The Japanese Market for Prefilled Syringes
10.4.1.1. Regulation of Combination Products in Japan
10.4.1.2. Primary Pharmaceutical Packaging Market in Japan

10.4.1.3. State of the Market: Drugs and Companies
10.4.2. Indian Market for Prefilled Syringes, 2013
10.4.3. Indonesian Market for Prefilled Syringes, 2014

11. GLOBAL PREFILLED SYRINGES MARKET FORECAST, 2014 - 2024
11.1. Background
11.2. Scope and Methodology
11.3. Global Market Size and Forecast
11.3.1. Prefilled Syringes for Vaccines
11.3.2. Prefilled Syringes for Drugs
11.3.2.1. Prefilled Syringes for Anticoagulants
11.3.2.2. Prefilled Syringes for Diabetes
11.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
11.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
11.3.2.5. Prefilled Syringes for Anti-Anaemic Drugs
11.3.2.6. Prefilled Syringes for Other Drug Classes
11.3.3. Prefilled Diluent Syringes, Prefilled Flush Syringes and Prefilled Syringes for Contrast Agents
11.3.4. Overall Global Market Size
11.4. Regional Market Size and Forecast: US, Europe, China and Rest of the World

12. INTERVIEW TRANSCRIPTS
13. CONCLUSION
13.1. The Shift from Vials to Prefilled Syringes
13.2. Plastic Syringes to Outperform Glass Syringes
13.3. Consolidated Market with Five Established Players; New Entrants Driving Innovation
13.4. Growth of Biologics, Rising Trend of Self-Medication and Many Other Factors will Fuel the Growth
13.5. Double-Digit Growth Expected to Continue Over the Coming Decade
13.6. Despite Being Full of Opportunities, Challenges Remain
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

LIST OF FIGURES

Figure 2.1 Market Evolution: 2013, 2019, 2024 (Number of Units)
Figure 2.2 Market Landscape: Geographical Trends
Figure 3.1 Prefilled Syringes: Market Landsacpe by Manufacturer
Figure 4.1 Global Prevalence of Diabetes: Distribution by Countries, 2013 (Million, %)
Figure 4.2 Numbers of Biologics Approved by the USFDA, 2009-2013
Figure 5.1 Sales of Leading Drugs Available in Prefilled Syringes, 2013 (USD Million)
Figure 5.2 Humira Global Sales, 2003-2013 (USD Million)
Figure 5.3 Enbrel US Sales, 2002-2013 (USD Million)
Figure 5.4 Copaxone Sales, 2001-2013 (USD Million)
Figure 5.5 Copaxone Unit Sales, 2000-2008: Distribution by Vials and Prefilled Syringes (Million)
Figure 5.6 Numbers of Biosimilars in Development for Anti-Rheumatics
Figure 5.7 Numbers of Biosimilars in Development for Multiple Sclerosis Drugs
Figure 5.8 Numbers of Biosimilars in Development for Anticoagulants
Figure 5.9 Numbers of Biosimilars in Development for Anti-Virals
Figure 7.1 Becton Dickinson Medical, 2013: Sales by Business Divisions (USD Million, %)
Figure 7.2 Gerresheimer, 2013: Sales by Business Divisions (EUR Million, %)
Figure 7.3 Nipro Corporation: Sales by Business Divisions, 2013 (YEN Billion, %)
Figure 7.4 SCHOTT: Sales by Business Divisions, 2013 (EUR Million, %)
Figure 7.5 West Pharmaceutical Services: Sales by Business Divisions, 2013 (USD Million, %)
Figure 7.6 Unilife Corporation: Sales, FY 2011 - FY 2013 (USD '000)
Figure 8.1 Domestic Prefilled Syringe Manufacturers in China: Annual Production Capacities, 2012 (Million Units)
Figure 8.2 Shandong Weigao: Prefilled Syringes Revenue (RMB Million), 2009-2013

Figure 8.3 Terumo Corporation: Sales by Business Divisions, 2013 (YEN Billion, %)
Figure 9.1 Common Medication Errors (%)
Figure 9.2 Common Sources of Medication Errors (%)
Figure 9.3 Prefilled Syringe Recalls, 2002-2014: By Type of Issue
Figure 10.1 The US Vaccines Market: By Type of Packaging (%)
Figure 10.2 European Vaccines Market: By Type of Packaging (%)
Figure 10.3 Japanese Prefilled Syringes Market: By Material of Barrel (%)
Figure 11.1 Prefilled Syringes Price Curve, 2014 – 2024 (USD per unit)
Figure 11.2 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.3 Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.4 Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.5 Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.6 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)

Figure 11.7 Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.8 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.9 Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.10 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.11 Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.12 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.13 Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.14 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.15 Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.16 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.17 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.18 Global Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.19 Global Prefilled Syringes, Units Growth by Category, 2014 - 2024 (Base Scenario, USD Million)

Figure 11.20 Global Prefilled Syringes, Sales Forecast, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.21 Global Prefilled Syringes, Sales Growth by Category, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.22 Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.23 Regional Prefilled Syringes, Sales Forecast, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.24 Prefilled Syringes Market, Distribution by Regions, 2013 - 2024 (%)
Figure 13.1 Prefilled Syringes Market: 2014, 2019 and 2024 (Units, Billions)
Figure 13.2 Prefilled Syringes Market: 2014, 2019, 2024 (USD Billion)


LIST OF TABLES

Table 3.1 List of Drugs which Shifted Their Presentation to Prefilled Syringe Systems in the US
Table 3.2 Classification of Prefilled Syringes
Table 3.3 Advantages of Glass as Barrel Material
Table 3.4 Prefilled Glass Syringe Recalls
Table 3.5 Advantages of Plastic Polymers as Barrel Material
Table 3.6 Pharmaceutical Filling Lines - Process Flow by Type of Prefilled Syringe
Table 3.7 Prefilled Syringe Systems Available in the Market, 2014: A Comparison, By Manufacturer
Table 3.8 Glass Prefilled Syringes Available in the Market, 2014

Table 3.9 Plastic Prefilled Syringes Available in the Market, 2014
Table 4.1 Population Over 65 in the US and Selected Countries in Europe, 2010, 2015 and 2020 (%)
Table 4.2 List of Auto-injector/Pen-injector Systems - Approved in 2013-2014
Table 4.3 List of Auto-injector/Pen-injector Systems (Using Prefilled Syringes) Available in the Market
Table 4.4 List of Safety Device Manufacturers
Table 5.1 Drugs Approved in Prefilled Syringes, 2013-2014
Table 5.2 List of Other Drugs Sold in Prefilled Syringes
Table 5.3 List of Pipeline Drugs Using Prefilled Syringe Systems,
Table 5.4 Anti-rheumatics (Injectables) Sales, 2013: Distribution by Leading Drugs (USD Million, %)
Table 5.5 Anti-rheumatics (Injectables) Drugs Available in Prefilled Syringes, 2014
Table 5.6 Anti-rheumatic Drugs (Injectables) Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 5.7 Multiple Sclerosis (Injectables) Sales, 2013: Distribution by Leading Drugs (USD Million, %)
Table 5.8 Multiple Sclerosis Drugs (Injectables) Available in Prefilled Syringes, 2014
Table 5.9 Multiple Sclerosis Drugs (Injectables) available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 5.10 Anticoagulants Sales (Injectables), 2013: Distribution by Leading Drugs (USD

illion, %)
Table 5.11 Anticoagulants (Injectables) Available in Prefilled Syringes, 2014
Table 5.12 Anticoagulants (Injectables) available in Prefilled Format: Patent Expiry and Biosimilars/Generics Development
Table 5.13 Anti-virals (Injectables) Sales, 2013: Distribution by Leading Drugs (USD Million, %)
Table 5.14 Anti-virals (Injectables) Available in Prefilled Syringes, 2014
Table 5.15 Anti-virals (Injectables) available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 5.16 Anti-Diabetes Market: Distribution by Leading Drugs (USD Million, %)
Table 5.17 Vaccines (Injectables) Sales, 2013: Distribution by Leading Vaccines (USD Million, %)
Table 5.18 Leading Vaccines (Injectables) Available in Prefilled Syringes, 2014
Table 5.19 Contrast Agents Available in Prefilled Syringes, 2014
Table 6.1 Drugs Marketed in Prefilled Diluent Syringes
Table 6.2 Prefilled Syringes for Lyophilised Drugs
Table 6.3 Drugs Marketed in Dual/Multi-Chamber Prefilled Syringes
Table 7.1 Features of Gx Glass Prefilled Syringe
Table 7.2 Features of ClearJect Prefilled Syringe
Table 7.3 Features of syriQ Prefilled Syringe
Table 7.4 Features of syriQ Injentle Prefilled Syringe
Table 7.5 Features of TopPac Prefilled Syringe
Table 7.6 Features of EZ-Fill Prefilled Syringe
Table 7.7 Features of Daikyo CZ Prefilled Syringe
Table 8.1 Domestic Prefilled Syringe Manufacturers in China: Comparison of Product Portfolio
Table 9.1 SWOT Analysis
Table 9.2 Prefilled Syringe Recalls, 2003-2014
Table 9.3 List of Marketed/Pipeline Needleless Injection Devices

Table 10.1 Seasonal Flu Vaccines in the US, 2013-2014
Table 10.2 Drugs Approved in Prefilled Syringes Format in Japan
Table 11.1 Prefilled Syringes Price Estimate (USD per unit)
Table 11.2 Vaccines Administered Via Prefilled Syringes
Table 11.3 List of Anticoagulants and Administration Route
Table 11.4 List of Anticoagulants Sold in Prefilled Syringes
Table 11.5 List of Multiple Sclerosis Drugs and Administration Route
Table 11.6 List of Multiple Sclerosis Drugs Sold in Prefilled Syringes
Table 11.7 List of Anti-Arthritic Drugs and Administration Route
Table 11.8 List of Anti-Arthritic Drugs Sold in Prefilled Syringes
Table 11.9 List of Anti-Anaemic Drugs and Administration Route
Table 11.10 List of Anti-Anaemic Drugs Sold in Prefilled Syringes
Table 11.11 List of Other Drugs Sold in Prefilled Syringes
Table 11.12 List of Contrast Agents using Prefilled Syringes
Table 14.1 Sales of Leading Drugs Available in Prefilled Syringes, 2013 (USD Million)
Table 14.2 Humira Global Sales, 2003-2013 (USD Million)
Table 14.3 Enbrel US Sales, 2002-2013 (USD Million)
Table 14.4 Copaxone Sales, 2001-2013 (USD Million)
Table 14.5 Copaxone Unit Sales, 2000-2008: By Vials and Prefilled Syringes (Million)
Table 14.6 Becton Dickinson Medical, 2013 - Sales by Business Divisions (USD Million, %)
Table 14.7 Gerresheimer, 2013 - Sales by Business Divisions (EUR Million, %)
Table 14.8 Nipro Corporation, 2013 - Sales by Business Divisions (YEN Billion, %)

Table 14.9 SCHOTT, 2013 - Sales by Business Divisions (EUR Million, %)
Table 14.10 West Pharmaceutical Services, 2013 - Sales by Business Divisions (USD Million, %)
Table 14.11 Unilife Corporation, Sales FY 2011 – FY 2013 (USD '000)
Table 14.12 Domestic Prefilled Syringe Manufacturers in China - Annual Production Capacities, 2012 (Million Units)
Table 14.13 Shandong Weigao: Revenue from Prefilled Syringes (RMB Million), 2009-2013
Table 14.14 Terumo Corporation, 2013: Sales by Business Divisions (YEN Billion, %)
Table 14.15 Prefilled Syringes Price Curve, 2014 – 2024 (USD per unit)
Table 14.16 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.17 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.18 Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.19 Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.20 Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.21 Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)

Table 14.22 Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.23 Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.24 Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.25 Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.26 Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.27 Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.28 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.29 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.30 Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.31 Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.32 Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.33 Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.34 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.35 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)

Table 14.36 Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.37 Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.38 Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.39 Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.40 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.41 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.42 Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.43 Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.44 Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.45 Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.46 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.47 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.48 Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.49 Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)

Table 14.50 Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.51 Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.52 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.53 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.54 Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.55 Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.56 Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.57 Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.58 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.59 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.60 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.61 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.62 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)

Table 14.63 Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.64 Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.65 Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.66 Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.67 Regional Prefilled Syringes, Sales Forecast 2014 - 2024 (Base Scenario, USD Million)
Table 14.68 Regional Prefilled Syringes, Sales Forecast 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.69 Regional Prefilled Syringes, Sales Forecast 2014 - 2024 (Optimistic Scenario, USD Million)

To order this report: Prefilled Syringes Market (2nd Edition), 2014-2024
http://www.reportlinker.com/p02243611/Prefilled-Syringes-Market-2nd-Edition-2014-2024.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved


Related medicine technology :

1. Prefilled Syringes Market (Glass and Plastic) - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2013 - 2019
2. Prefilled Syringes Market, 2013 - 2023
3. Prefilled Syringes 2013 Market Report
4. Prefilled Syringes to 2018 - Devices, Drugs, Markets, Players and Prospects
5. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
6. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
7. Dual Chamber Syringes & Injectors. Devices, Therapeutics, Markets and Forecasts
8. Global Markets for Emerging Insulin Drug and Delivery Technologies - Focus on Syringes and Vials
9. Integrated Safety Syringes to 2016: Devices, Markets Players and Prospects
10. Dual Chamber Syringes & Injectors
11. West Announces the Commercial Introduction of a Novel Intradermal Adapter for Disposable Syringes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):